Brainsway Ltd BWAY.OQ, BWAY.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Jerusalem Israel-based company is expected to report a 22.5% increase in revenue to $10.168 million from $8.3 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Brainsway Ltd is for earnings of 1 cent per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the advanced medical equipment & technology peer group is "Buy".
Wall Street's median 12-month price target for Brainsway Ltd is 12.55, above its last closing price of $10.54.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | 0.00 | 0.00 | 0.04 | Beat | |
Dec. 31 2024 | -0.02 | -0.02 | 0.00 | Beat | 100 |
Dec. 31 2023 | -0.01 | -0.01 | 0.00 | Beat | 100 |
Jan. 1 0001 | -0.04 | -0.03 | -0.02 | Beat | 33.3 |
Jan. 1 0001 | -0.09 | -0.10 | Missed | -11.1 | |
Mar. 31 2023 | -0.10 | -0.14 | Missed | -33.3 | |
Dec. 31 2022 | -0.13 | -0.13 | -0.24 | Missed | -77.8 |
Sep. 30 2022 | -0.06 | -0.06 | -0.30 | Missed | -400 |
This summary was machine generated November 8 at 16:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。